This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

While Victoza sales are falling as patients switch to newer, once-weekly drugs ... shortages list, mainly due to pressures on Novo Nordisk's production capacity for its entire GLP-1 franchise ...

It's possible that Alzheimer's disease could be added to the lengthening list of ... injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able ...

“The recent explosion in irresponsible and misleading advertising about compounded GLP-1 drugs ... when both drugs were added to the FDA's shortage list. When the FDA removed tirzepatide ...

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.